The use of hormone therapy up to 5 years after onset of menopause is associated with a lower risk for ischemic and hemorrhagic stroke compared with late hormone therapy initiation or no hormone therapy use.
A recent literature review and meta-analysis indicates that growth hormone therapy may reduce the risk for fracture in patients with osteoporosis.
To update its 2012 recommendation, the US Preventive Services Task Force reviewed evidence on the benefits and harms of systemic hormone therapy for the prevention of chronic conditions in postmenopausal women.
There may be other roles of estradiol therapy besides relief from
menopause-related symptoms, including limiting effects of stress on working memory.
Rates of cBHT prescriptions are not yet being systemically tracked, and few data exist to demonstrate the safety, efficacy, or utility of the treatment.
Lifestyle modification and an individualized treatment approach are effective strategies for managing menopausal symptoms in breast cancer survivors who are largely advised to avoid hormone replacement therapy.
The newly released guidelines include updated language to reflect DSM-V changes, greater flexibility in treatment, and recommendations for CVD, bone health, and prostate cancer screening.
The effect of 1 year of cross-sex hormone therapy on bone mineral density was examined in transgender men and women.
Primary prevention of cardiovascular disease through risk factor modification, including tobacco cessation, maintenance of a body mass index, and management of abnormal lipid levels, diabetes, and hypertension, is of great importance for the health of transgender individuals.
HRT in postmenopausal women was linked to lower CAC scores and a lower risk of long-term, all-cause mortality.
